Michael R. Mcmullen Sells 8,966 Shares of Agilent Technologies, Inc. (NYSE:A) Stock

Agilent Technologies, Inc. (NYSE:A) CEO Michael R. Mcmullen sold 8,966 shares of Agilent Technologies stock in a transaction that occurred on Tuesday, April 13th. The stock was sold at an average price of $132.50, for a total transaction of $1,187,995.00. Following the sale, the chief executive officer now owns 270,158 shares of the company’s stock, valued at approximately $35,795,935. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website.

Shares of A stock traded up $1.31 during trading on Thursday, reaching $133.28. The company’s stock had a trading volume of 2,115,571 shares, compared to its average volume of 1,686,299. The business has a fifty day moving average price of $124.07 and a 200-day moving average price of $117.64. The company has a quick ratio of 1.84, a current ratio of 2.33 and a debt-to-equity ratio of 0.47. The company has a market cap of $40.61 billion, a price-to-earnings ratio of 58.10, a price-to-earnings-growth ratio of 3.82 and a beta of 1.04. Agilent Technologies, Inc. has a one year low of $73.42 and a one year high of $136.98.

Agilent Technologies (NYSE:A) last announced its quarterly earnings data on Monday, February 15th. The medical research company reported $1.06 EPS for the quarter, topping the Zacks’ consensus estimate of $0.89 by $0.17. Agilent Technologies had a net margin of 13.47% and a return on equity of 21.02%. The business had revenue of $1.55 billion for the quarter, compared to analyst estimates of $1.43 billion. During the same quarter in the previous year, the firm posted $0.81 earnings per share. Research analysts anticipate that Agilent Technologies, Inc. will post 3.67 EPS for the current year.

Agilent Technologies declared that its board has approved a stock buyback plan on Tuesday, February 16th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to purchase up to 5% of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its shares are undervalued.

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 28th. Shareholders of record on Tuesday, April 6th will be given a dividend of $0.194 per share. This represents a $0.78 annualized dividend and a yield of 0.58%. The ex-dividend date is Monday, April 5th. Agilent Technologies’s dividend payout ratio (DPR) is currently 23.78%.

A has been the subject of several analyst reports. Redburn Partners upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating in a research report on Friday, March 19th. MKM Partners began coverage on shares of Agilent Technologies in a report on Wednesday, December 23rd. They set a “buy” rating and a $57.00 price objective for the company. Cowen boosted their price objective on shares of Agilent Technologies from $125.00 to $135.00 and gave the company an “outperform” rating in a report on Wednesday, February 17th. Bank of America upgraded shares of Agilent Technologies from a “neutral” rating to a “buy” rating and set a $147.00 price objective for the company in a report on Wednesday, February 17th. Finally, Mizuho began coverage on shares of Agilent Technologies in a report on Tuesday, January 12th. They set a “buy” rating and a $51.00 price objective for the company. Nine analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Agilent Technologies has a consensus rating of “Buy” and a consensus target price of $105.40.

Hedge funds have recently added to or reduced their stakes in the stock. Veriti Management LLC lifted its holdings in shares of Agilent Technologies by 3.3% in the first quarter. Veriti Management LLC now owns 2,394 shares of the medical research company’s stock worth $304,000 after acquiring an additional 77 shares during the last quarter. Raymond James Trust N.A. lifted its holdings in shares of Agilent Technologies by 2.3% in the fourth quarter. Raymond James Trust N.A. now owns 3,707 shares of the medical research company’s stock worth $440,000 after acquiring an additional 84 shares during the last quarter. MainStreet Investment Advisors LLC lifted its holdings in shares of Agilent Technologies by 2.3% in the fourth quarter. MainStreet Investment Advisors LLC now owns 4,072 shares of the medical research company’s stock worth $482,000 after acquiring an additional 91 shares during the last quarter. Jacobi Capital Management LLC lifted its holdings in shares of Agilent Technologies by 80.0% in the fourth quarter. Jacobi Capital Management LLC now owns 225 shares of the medical research company’s stock worth $27,000 after acquiring an additional 100 shares during the last quarter. Finally, Kestra Private Wealth Services LLC lifted its holdings in shares of Agilent Technologies by 4.3% in the fourth quarter. Kestra Private Wealth Services LLC now owns 2,511 shares of the medical research company’s stock worth $295,000 after acquiring an additional 104 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.

Featured Article: How Do I Invest in Dividend Stocks

Insider Buying and Selling by Quarter for Agilent Technologies (NYSE:A)

Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.